Audentes Therapeutics Inc (NASDAQ:BOLD)’s share price hit a new 52-week high on Tuesday . The stock traded as high as $58.99 and last traded at $58.91, with a volume of 9093752 shares. The stock had previously closed at $28.61.

BOLD has been the subject of a number of recent research reports. Piper Jaffray Companies downgraded Audentes Therapeutics from an “overweight” rating to a “neutral” rating and increased their price objective for the company from $55.00 to $60.00 in a report on Tuesday. Robert W. Baird raised Audentes Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Tuesday. William Blair reaffirmed a “hold” rating on shares of Audentes Therapeutics in a report on Wednesday, August 7th. ValuEngine lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Finally, BidaskClub cut Audentes Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $44.50.

The business’s 50 day moving average is $27.71 and its two-hundred day moving average is $33.11. The firm has a market cap of $1.33 billion, a P/E ratio of -17.28 and a beta of 1.77.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.07) by $0.07. During the same quarter in the prior year, the firm posted ($0.97) EPS. On average, equities research analysts predict that Audentes Therapeutics Inc will post -4.13 EPS for the current fiscal year.

In other news, Director Louis G. Lange sold 10,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $32.16, for a total value of $321,600.00. Following the transaction, the director now directly owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew R. Patterson sold 14,426 shares of the company’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $30.00, for a total value of $432,780.00. Following the sale, the chief executive officer now owns 127,820 shares in the company, valued at approximately $3,834,600. The disclosure for this sale can be found here. Company insiders own 5.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Audentes Therapeutics by 14.2% during the second quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock worth $126,204,000 after acquiring an additional 413,768 shares in the last quarter. Great Point Partners LLC raised its holdings in shares of Audentes Therapeutics by 29.2% during the third quarter. Great Point Partners LLC now owns 2,485,000 shares of the biotechnology company’s stock valued at $69,804,000 after purchasing an additional 562,063 shares during the period. Vanguard Group Inc. raised its holdings in shares of Audentes Therapeutics by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,971,206 shares of the biotechnology company’s stock valued at $74,629,000 after purchasing an additional 84,659 shares during the period. Victory Capital Management Inc. boosted its position in shares of Audentes Therapeutics by 2.7% during the 2nd quarter. Victory Capital Management Inc. now owns 904,221 shares of the biotechnology company’s stock worth $34,233,000 after purchasing an additional 23,620 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Audentes Therapeutics by 49.2% during the 3rd quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company’s stock worth $21,721,000 after purchasing an additional 255,086 shares in the last quarter. Institutional investors own 98.08% of the company’s stock.

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Article: What is an economic bubble?

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.